P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough

Wen-Wen Cui a,b,1, Si-Yu Wang a,1, Yu-Qing Zhang a,1, Yao Wang c, Ying-Zhe Fan c, Chang-Run Guo a, Xing-Hua Li a, Yun-Tao Lei a, Wen-Hui Wang a, Xiao-Na Yang a, Motoyuki Hattori e, Chang-Zhu Li d,∗, Jin Wang a,b,∗, Ye Yu a,b,∗

a School of Basic Medicine and Clinical Pharmacy and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China
b Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
c Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200025, China
d State Key Laboratory of Utilization of Woody Oil Resource, Hunan Academy of Forestry, Changsha 410004, China
e State Key Laboratory of Genetic Engineering, Collaborative Innovation Center of Genetics and Development, Shanghai Key Laboratory of Bioactive Small Molecules, Department of Physiology and Neurobiology, School of Life Sciences, Fudan University, Shanghai 200438, China

A R T I C L E   I N F O

Article history:
Received 3 November 2021
Received in revised form 16 March 2022
Accepted 27 March 2022
Available online 31 March 2022

Keywords:
Gefapixant/AF-219
P2X3 receptors
Refractory chronic cough
Binding sites
Subtype selectivity

A B S T R A C T

Gefapixant/AF-219, a selective inhibitor of the P2X3 receptor, is the first new drug other than dextromethorphan to be approved for the treatment of refractory chronic cough (RCC) in nearly 60 years. To date, seven P2X subtypes (P2X1-7) activated by extracellular ATP have been cloned, and subtype selectivity of P2X inhibitors is a prerequisite for reducing side effects. We previously identified the site and mechanism of action of Gefapixant/AF-219 on the P2X3 receptor, which occupies a pocket consisting of the left flipper (LF) and lower body (LB) domains. However, the mechanism by which AF-219 selectively acts on the P2X3 receptor is unknown. Here, we combined mutagenesis, chimera construction, molecular simulations, covalent occupation and chemical synthesis, and find that the negative allosteric site of AF-219 at P2X3 is also present in other P2X subtypes, at least for P2X1, P2X2 and P2X4. By constructing each chimera of AF-219 sensitive P2X3 and insensitive P2X2 subtypes, the insensitive P2X2 subtype was made to acquire the inhibitory properties of AF-219 and AF-353, an analog of AF-219 with higher affinity. Our results suggest that the selectivity of AF-219/AF-353 for P2X3 over the other P2X subtypes is determined by a combination of the accessibility of P2X3 binding site and the internal shape of this pocket, a finding that could provide new perspectives for drug design against P2X3-mediated diseases such as RCC, idiopathic pulmonary fibrosis, hypertension and overactive bladder disorder.

© 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

P2X receptors are an important class of ATP-gated trimeric ion channels, and seven homotrimers or heterotrimers of P2X1-7 have been identified in most tissues [1]; they are implicated in a variety of physiological and pathological functions such as synaptic transmission, sensory perception, muscle contraction, pain, thrombosis and immune regulation, and therefore are an important class of new drug targets [2]. Although there is no specific drug that is currently available for clinical treatments, a few small molecules targeting P2X3, P2X4 and P2X7 have been identified, especially those targeting P2X3 and P2X7, which have shown significant efficacy in the clinical trials [1,3]. For example, Gefapixant (AF-219), an antagonist of the P2X3 receptor, has shown significant efficacy in refractory chronic cough (RCC) and is the first new drug other than dextromethorphan to be approved for the treatment for RCC in the last 60 years [4-9]. Similarly, other P2X3 antagonists BAY-1817080 [10,11], BAY-1902607 [12], BLU-5937 [13,14] and S-600918 [15,16] are all being studied in phase II or phase III clinical trials.

https://doi.org/10.1016/j.csbj.2022.03.030
2001-0370© 2022 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
trials as treatment for RCC. Outside of the respiratory system, the P2X3 receptor antagonist BAY-1817080 is being used to treat endometriosis [17] and overactive bladder disorder [18]. The P2X4 receptor antagonist NC-2600 is in phase I clinical trials for the treatment of neuropathic pain [19], and has shown promising data in the treatment of chronic cough without taste disturbance [20]. Several P2X7 antagonists being investigated for the treatment of rheumatoid arthritis (CE-224,535 [21], EVT 401 [22] and AZD 9056 [23,24]), inflammation (GSK-1482160 [25,26]), neuropathic pain (AFC-5128 [27] and RQ-00466749 [28]), major depressive disorder (JNJ-54175446 [29,30]), mood disorder (JNJ-55308942 [31,32]), multiple sclerosis and gastrocnemius dystrophy (AFC-
P2X receptors are mainly due to the following aspects: drugs that are distributed in different tissues and organs, and effective drug interactions are distributed in different tissues and organs, and effective drug selectivity is essential to reduce the side effects of drugs. However, highly conserved sequence of P2X receptors make subtype selectivity a challenge for drug discovery [11]. For example, P2X4 antagonists containing carbamazepine scaffolds have a stable and pronounced inhibitory effect on human P2X4 (hP2X4), in addition to hP2X1, hP2X3 and hP2X7 [33]. Second, the highly conserved amino acids at the ATP-binding pocket limit the specificity of orthosteric modulators, making the development of selective orthosteric modulators extremely difficult [34]. The commonly used competitive inhibitor TNP-ATP has strong effects on both P2X1 and P2X3, and weak effects on P2X2 and P2X4 [35,36]. Third, subtle sequence differences between the human- and rodent-derived P2X receptors make some subtype-selective drug molecules troublesome with species differences, which hinders the exploration of drugs in model animals and human clinical trials. For example, the antagonist of P2X3 receptors, RO-51, has much stronger affinity for rodents than for human P2X3, while carbamazepine-like antagonists of the P2X4 receptor and BX430 are both more effective against hP2X4 and less effective or ineffective against rodent P2X4 [33,37]. CW791343, a molecule targeting P2X7 receptors, has an opposite effect on human and murine P2X7 [38].

AF-219 (IC_{50}, the concentration yielding half of the maximal inhibition, = 42.6 ± 2.9 nM) and AF-353 (IC_{50} = 9.9 ± 1.1 nM), two compounds with the same structural core (see below, Fig. 7), are negative allosteric modulators specifically targeting P2X3 receptors (with IC_{50} values >10 μM on P2X1, P2X2, P2X4, P2X5 and P2X7) [39-41]. We identified a mechanism by which the binding of these two compounds prevented the movement of the left flipper (LF) domain and thus exerted an inhibitory effect [42]. However, the structural basis for the selectivity of AF-219 and AF-353 in the highly homologous P2X subtypes remains unexplored, an issue that is critical for drug discovery of the P2X receptor.

Here, we investigated the mechanism for the generation of P2X3 subtype and species specificity of these two allosteric small molecules through chimera construction, click chemical covalent modification of proteins, structural modification of AF-353/AF-219, and dynamic analysis of protein-small molecule interactions. We found that: 1. pocket accessibility and access pathways are extremely important for drug accessibility and species differences; 2. the matching of pocket internal shape to small molecule drugs significantly affects the binding and action of the small molecule drug; 3. subtle differences in pocket overall structure between different P2X receptor subtypes are also involved in the determination of drug action specificity. Meanwhile, we further confirmed our findings by integrating various potential influencing factors into the chimera to obtain the ability of AF-219/AF-353 inhibition using the AF-219/AF-353 insensitive P2X2 subtype as an example. Our study on the subtype specificity of AF-219/AF-353 will provide new perspectives for further RCC drug designs.

2. Materials and methods

2.1. Molecular and cell biology

The rat P2X2 (rP2X2), rat P2X3 (rP2X3), rat P2X4 (rP2X4) and rat P2X7 (rP2X7) plasmids were kindly gifted by Drs. Alan North and Lin-Hua Jiang. The human P2X1 (hP2X1) cDNA was synthesized by Gikai Gene and subcloned by us into the pcDNA3.1 vector. Chicken P2X3 (cP2X3) plasmid was synthesized and subcloned into pEGFP-N1 by Beijing Genomics Institute (BGI). Mutants and chimeras were constructed by KOD-Plus mutagenesis kit (Toyobo) and confirmed by DNA sequencing. HEK293 cells were bought from Cell Bank, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. The cells were cultured in medium containing 88% Dulbecco’s Modified Eagle Medium (DMEM) (Corning), 10% fetal bovine serum (FBS) (PAN), 1% Glutamax (Gibco) and 1% penicillin/streptomycin (Hyclone) at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. Plasmids were transfected into HEK293 cells by calcium phosphate transfection [43]. In brief, 2.5 μg plasmid DNA was mixed directly with 100 μL 0.25 M CaCl2 solution and then mixed slowly into 2× HBS solution to ensure the formation of calcium phosphate-DNA precipitate. 2× HBS solution contains (in mM) 140 NaCl, 1.5 Na2HPO4, 50 HEPES, and the pH is adjusted to 6.96.

2.2. Electrophysiological recordings

Conventional whole-cell and nystatin-perforated patch-clamp recording methods were used at room temperature (25 ± 2 °C) [44-47]. The electrophysiological measurements were performed 24–48 h after transfection. The resistance of patch pipettes was 3–5 megOhms (mΩ) pulled from glass capillaries on a two-stage puller (PC-100, Narishige) when filled with the pipette solution containing (in mM) 120 KCl, 30 NaCl, 1 MgCl2·6H2O, 0.5 CaCl2·2H2O, 10 HEPES and 5 EGTA adjusted to pH 7.35–7.40. The bath solution contains (in mM) 150 NaCl, 0.5 KC1, 10 glucose, 2 CaCl2·2H2O, 10 HEPES and 1 MgCl2·6H2O adjusted to pH 7.35–7.40. For nystatin-perforated patch-clamp recording, the pipette solution contains (in mM) 75 K2SO4, 55 KC1, 5 MgSO4 and 10 HEPES, pH 7.2. Membrane currents were measured using an Axon patch 200B patch clamp amplifier (Molecular Devices, USA). A low-pass Bessel filter was used to filter currents at 2 kHz. All currents were digitized using a Digidata 1550B interface and pCLAMP software (Molecular Devices). The membrane potential was held at −60 mV. To avoid the rundown of currents in multi-dose applications of ATP, nystatin (0.15 mg/mL)-perforated patch clamp technique was used with application intervals of saturated-concentration ATP at about 8 min, which recording was discarded when current amplitudes in respond to the first two ATP applications varied more than 20%. Currents of rP2X2 and rP2X7 receptors were recorded by conventional whole-cell patch configuration, while other subtypes were recorded by nystatin-perforated recordings. Electrophysiological recordings were repeated at least 3 times for each mutation or for each concentration of the drug, and these independent experiments are derived from cells transfected at least 2–3 times on different days. Data were normalized to the average value of the first two ATP-evoked currents. All inhibitors were pre-applied for 1 min and then co-applied with the agonist. N-phenylmaleimide (NPM) was diluted to ~0.5–1 mM and immediately perfused to the cell membrane for 5 min and 2 min, respectively. AF-353 was purchased from Sigma-Aldrich, and AF-219 and AF-219–1 were synthesized according to our previous description [42].
2.3. Chemical synthesis of AF-219-2

2.3.1. 2-(sec-butyl)-4-methoxyphenol

Following the prepare procedure of 2-isopropyl-4-methoxyphenol described in our previous work [42], 2-(sec-butyl)-4-methoxyphenol was prepared from 1-(2-hydroxy-5-methoxyphenyl)ethan-1-one and ethylmagnesium chloride as colorless oil in 68% yield for two steps.

2.3.2. 2-(sec-butyl)-4-methoxyphenyl 4-methylbenzenesulfonate

To a solution of 2-(sec-butyl)-4-methoxyphenol (1.0 mmol) in methylene chloride (DCM, 10 mL) was added tosyl chloride (1.1 mmol) and Et₃N (1.1 mmol). The reaction mixture was stirred at room temperature until completion, and water (20 mL) was added into the mixture. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to give 2-(sec-butyl)-4-methoxyphenyl 4-methylbenzenesulfonate as light-yellow oil in 95% yield.

2.3.3. 2-(sec-butyl)-5-chloro-4-methoxyphenyl 4-methylbenzenesulfonate

To a solution of 2-(sec-butyl)-4-methoxyphenyl 4-methylbenzenesulfonate (1.0 mmol) in glacial acetic acid (5 mL) was added N-Chlorosuccinimide (NCS, 1.2 mmol). The reaction mixture was stirred at room temperature until completion, and saturated NaHCO₃ solution was added into the mixture. The aqueous layer was extracted with ethyl acetate (EtOAc). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to give 2-(sec-butyl)-5-chloro-4-methoxyphenyl 4-methylbenzenesulfonate as a white solid in 72% yield.

2.3.4. 2-(sec-butyl)-5-chloro-4-methoxyphenol

To a solution of 2-(sec-butyl)-5-chloro-4-methoxyphenol (1.0 mmol) in methylene chloride (DCM, 10 mL) was added tosyl chloride (1.1 mmol) and Et₃N (1.1 mmol). The reaction mixture was stirred at room temperature until completion, and water (20 mL) was added into the mixture. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to give 2-(sec-butyl)-5-chloro-4-methoxyphenol 4-methylbenzenesulfonate as a white solid in 95% yield.
aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na$_2$SO$_4$, filtered, and concentrated in vacuo. The residue was purified by flash chromatography to give 2-(sec-butyl)-5-chloro-4-methoxyphenol as a white solid in 72% yield.

2.3.5. 2-(2-(sec-butyl)-5-chloro-4-methoxyphenoxy)acetonitrile

Following the prepare procedure of 2-(2-isopropyl-4-methoxy phenoxy)acetonitrile described in our previous work [42], 2-(2-(sec-butyl)-5-chloro-4-methoxyphenoxy)acetonitrile was prepared from 2-(sec-butyl)-5-chloro-4-methoxyphenol as colorless oil in 72% yield.

2.3.6. 5-(2-(sec-butyl)-5-chloro-4-methoxyphenoxy)pyrimidine-2,4-diamine (AF-219-2)

Following the prepare procedure of 5-(2-isopropyl-4-methoxy phenoxy)pyrimidine-2,4-diamine described in our previous work [42], 5-(2-(sec-butyl)-5-chloro-4-methoxyphenoxy)pyrimidine-2,4-diamine was prepared from 2-(2-(sec-butyl)-5-chloro-4-methoxyphenyl)acetonitrile as a white solid in 65% yield. $^1$H NMR (300 MHz, DMSO $d_6$) $\delta$ 7.27 (s, 1H), 6.95 (s, 1H), 6.63 (s, 1H), 6.30 (s, 2H), 5.80 (s, 2H), 3.80 (s, 3H), 3.04 (dd, $J = 14.1, 7.0$ Hz, 1H), 1.70–1.42 (m, 2H), 1.18 (d, $J = 6.9$ Hz, 3H), 0.80 (t, $J = 7.3$ Hz, 3H) (Fig. S2). ESI MS $m/z = 323.1$ [M+H]$^+$. 

2.4. Molecular dynamics (MD) simulations

The homology models of rP2X2WT, rP2X3WT and rP2X2gain were constructed based on the crystal structures of hP2X3 (PDB IDs: 55VJ and 5YVE) using MODELLER [48]. The alignments of the target sequences were made by ClustalW2 and manually adjusted to match published alignments [49]. The obtained model was checked and validated by ProCheck [50]. The energy-minimized structures of P2X3 were used as the initial structures for molecular simulations. A large 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, 300 K) bilayer, available in System Builder of DESMOND [51], was built to generate a suitable membrane system based on the OPM database [https://opm.phar.umich.edu] [52], in which the TM domain of the P2X could be embedded properly. The P2X/POPC system was dissolved in simple point charge (SPC) water molecules. Counter ions were then added to compensate for the net negative charge of the system. NaCl (150 mM) was added into the simulation box that represents background salt at physiological condition. The DESMOND default relaxation protocol was applied to each system prior to the simulation run. (1) 100 ps simulations in the NVT (constant number (N), volume (V), and temperature (T)) ensemble with Brownian kinetics using a temperature of 10 K with solute heavy atoms constrained; (2) 12 ps simulations in the NVT ensemble using a Berendsen thermostat with a temperature of 10 K and small-time steps with solute heavy atoms constrained; (3) 12 ps simulations in the NPT (constant number (N), pressure (P), and temperature (T)) ensemble using a Berendsen thermostat and barostat for 12 ps simulations at 10 K and 1 atm, with solute heavy atoms constrained; (4) 12 ps simulations in the NPT ensemble using a Berendsen thermostat and barostat at 300 K and 1 atm with solute heavy atoms constrained; (5) 24 ps simulations in the NPT ensemble using a Berendsen thermostat and barostat at 300 K and 1 atm without constraint. After equilibration, the MD simulations were performed for ~100–200 ns. Long-range electrostatic interactions were computed using a smooth Particle Mesh Ewald method. The trajectory recording interval was set to 200 ps and other default parameters of DESMOND were used during MD simulation runs. All simulations used the all-atom OPLS_2005 force field [53,54], which was used for proteins, ions, lipids and the SPC waters. All systems were close to overall stability after simulation (Fig. S1). The Simulation Interaction Diagram (SID) module in DESMOND was used for exploring the interaction analysis between AF-219 and P2X. All simulations were run on DELL T7920 graphic working station (with NVIDIA Tesla K40C-GPU). Preparation, analysis, and visualization were performed on a 12-CPU CORE T73610 graphic working station. The protein pockets are detected using Fpocket (https://fpocket.sourceforge.net/) [55] and the volume of the cavity is calculated on the TRAPP web server (https://trapp.h-its.org/trapp) [56].

2.5. Data analysis

All results are expressed as Mean ± S.E.M. or S.D., and statistics are analyzed using Student’s t test or ANOVA, for which *$P < 0.05$ and **$P < 0.01$ were considered as significant difference. Concentration-response curves were fitted to the Hill equation: $I/Imax = 1/(1+(IC_{50}/[inhibitor])^n)$, in which $I$ is the normalized current at a given of the concentration of the antagonists, $Imax$ is the maximum normalized current induced by the agonist (ATP), $[inhibitor]$ is the concentration of AF-219, AF-353, and synthesized analogs of AF-353, $IC_{50}$ is the antagonist concentration that is half maximally effective, $n$ is the Hill coefficient.

3. Results

3.1. The negative allosteric site of AF-219 on the P2X3 receptor is also present in other subtypes, but the accessibility of the small molecule differs from that of P2X3

We previously found that the relative motion of the LF and dorsal fin (DF) domains of P2X4 receptors is critical for the transition of the channel from the resting state to the open state [44]. Comparison of the resolved structures of hP2X3 [57] and rP2X7 [58] in the open state with those in the apo state revealed that relative movements of the LF and DF domains also occur in other P2X subtypes, indicating that, in addition to P2X4, this allostery may play an important role in other subtypes of channel gating. In a recent study, we also found that the P2X3 receptor antagonist AF-219 and its derivatives AF-353 and RO-51 bind within the allosteric site formed by the LF and lower body (LB) domains and exert an inhibitory effect by impeding the relative movement of the LF and DF domains during P2X3 opening (Fig. 1A and Ref. [42]). Whether this negative allosteric pocket exists only at the P2X3 receptors or whether there are other possibilities is not well understood.
To address this question, we covalently linked small molecules to specific amino acids of each subtype, corresponding to cystine mutation inside the AF-219 binding pocket, like V238C in rP2X3, to verify whether the opening of the other P2X subtypes would be affected if the relative movement of the LF and DF domains was blocked. We constructed mutants hP2X1 V252C, rP2X2 V249C, rP2X3 V238C, rP2X4 I252C and rP2X7 I251C at equal positions in five different subtypes (P2X5 and P2X6 receptors were not measured due to their ATP responses are almost undetectable), and then reacted with the introduced free thiol group (−SH) (Fig. 1B) using 1 mM N-phenylmaleimide (NPM) with 5 min pretreatment to achieve covalent occupation of the small molecule at this position. Compared with wild type (WT) P2X receptors, hP2X1 V252C, rP2X2 V249C, rP2X3 V238C and rP2X4 I252C have significantly impaired channel functions after forming a covalent linkage with NPM (Fig. 1C, D), indicating that the allosteric pocket recognizing AF-219/AF-353/RO-51 not only has the potential to allosterically regulate P2X3 receptors but also the other subtypes of P2X receptors are also prevalent, at least for hP2X1, rP2X2 and rP2X4. NPM modification of the rP2X7 I251C receptor was not carried out, as its ATP response was almost undetectable (Fig. S3).

When the concentration of NPM was reduced to 0.5 mM and the reaction time to 2 min, there was still a significant decrease in the ATP current rP2X3 V238C, while rP2X4 I252C and rP2X7 I252C showed no significant change (Fig. 1E, F), indicating that the accessibility of small molecules to this pocket was different among different subtypes.

3.2. Amino acid sequence differences at the entrance affect the small molecule accessibility to the negative allosteric site

To further confirm this point, we examined the cavity between the LF and LB domains in the structures of rP2X3 and zebrafish P2X4 (zfP2X4) (Fig. 2A, B). Consistent with above covalent modification results, a pocket consisting of amino acids in β1, β8 and β9 sheets of the LB and LF domains is present below the LF domain of both zfP2X4 and rP2X3 receptors. The difference is that in rP2X3, the entrance of the pocket is the glycine (G189), a residue without a bulky side chain, so that the pocket is accessible to small molecules (Fig. 2A). However, in zfP2X4, the corresponding residue is an arginine (R203), whose bulkier side chain makes the pocket inaccessible to small molecules (Fig. 2B).

Since any mutation of R203 in the rP2X4 or zfP2X4 receptors abolishes the activation of channels [59], it is difficult to verify the effect of reducing the side chain size of the entrance of putative allosteric site at the P2X4 receptor. However, by analyzing the sequences of P2X3 receptors of other species, it was found that in the chicken P2X3 (cP2X3) receptor, the identical position is an alanine (Fig. 2C), providing a good tool to study the accessibility of the AF-219 pocket in P2X3. Furthermore, AF-353, which has only one sulfonamide group substituted by an iodine atom, has a higher affinity (~10-fold) and stable inhibition of the P2X3 receptor compared with AF-219; our previous results also showed that AF-353 and other analogs do act in the same pocket formed by the LF and LB domains [42]. Therefore, we used AF-353 as a chemical tool...
in all subsequent functional analyses, and key findings were simultaneously validated with AF-219.

Consistent with our inference, since the amino acid corresponding to G189 of rP2X3 is alanine (A196 in cP2X3), 10 lM of AF-353 and 30 lM of AF-219 had no inhibitory effect on cP2X3 at all (Fig. 2D–G). Also, G189A mutation in rP2X3 abolished the inhibition of AF-353 and AF-219 (Fig. 2H–K). Notably, after mutating this site to glycine, cP2X3A196G then gained the ability to be significantly inhibited by AF-353/AF-219 (Fig. 2D–G), demonstrating the importance of the G189 position for small molecules to enter and act in the pocket below the LF domain. This also appears to be consistent with the finding that treatment with 0.5 mM/2 min NPM could modify rP2X3V238C, since the position corresponding to G189 is glycine, but not in rP2X4I252C where G189 corresponds to arginine (Fig. 1E, F).

### 3.3. Sequence changes in residues located deep in the allosteric pocket may prevent small molecules from binding deeper into the pocket

The difference in amino acid sequence at the entrance could explain the insensitivity of AF-219 to a few subtypes like P2X4 that have a bulkier side chain of amino acids at the entrance. In contrast, P2X2 contains the same glycine at position 201 (Fig. 2C–D), suggesting that the difference in amino acids at the entrance is not sufficient to fully explain the high selectivity of AF-219. To further illustrate this, we constructed a homology model of AF-219 in complex with rP2X2 (Fig. 3A).

The initial structure of the homology modeling suggests that in P2X2, AF-219 took a similar interaction as P2X3 (Fig. 3B). Further, we took ~200-ns time scale of MD simulations to investigate whether this interaction is stable. In the P2X3 receptor, the hydrophobic interaction of V61 with AF-219 is important for AF-219 binding, and mutation of V61R leads to a significant decrease in AF-219 affinity [42]. In P2X2, the amino acid in the identical position is I67, and this position is the only amino acid that differs in the direct interaction of AF-219 with rP2X2 or rP2X3 (Fig. 3B). To illustrate whether the binding of AF-219 is stable, we monitored the change in the distance between the Cα atom of I67 and the O atom of AF-219 during MD simulations (Fig. 3C), and we found that this distance changed significantly from 8.5 to 12 Å during simulations, suggesting that AF-219 is ‘forced’ to move out during MD simulations (Fig. 3C-E) due to the larger steric hindrance of Ile (I67 in rP2X2) than Val (V67 in rP2X3).

In fact, P2X2I67V partially obtained the inhibition of AF-353 compared to the WT P2X2 channel (with a maximum inhibition of ATP currents at 100 μM (maximal water solubility) = 67.8 ± 5.3%, IC50 >10 μM; Fig. 3F), a result suggesting that the binding and action of the small molecule antagonist require access to the deeper region of this allosteric pocket, and V61 contributes to the binding of small molecules entering the deeper region of the pocket.

### 3.4. The difference in pocket shape is another important factor in determining the role of small molecules

Although rP2X2I67V ‘gains’ AF-353-sensitivity, the IC50 value of AF-353 for rP2X2I67V differs nearly 1000-fold from that of rP2X3, suggesting that there are factors other than pocket accessibility...
and deep pocket size that influence AF-219/AF-353 binding. Because of the sequence differences in the amino acids that make up this pocket, we used Fpocket (https://fpocket.sourceforge.net) [59] to characterize this pocket of the rP2X2 receptor and found that in the resting state of rP2X2, this pocket is closer to the surface of the protein compared to rP2X3 (Fig. 4A). Furthermore, the root-mean-square deviation (RMSD) analysis of the amino acids constituting this pocket changed from 1 Å in the initial step to ~1.5 Å at the final snapshot of MD simulations (Fig. 4B), indicating that sequence differences may lead to significant structural rearrangements in this region. Interestingly, after MD simulations, the LF domain shifted downward to form an α-helical structure, and such a change resulted in a compressed pocket below the LF domain, thus making AF-219 difficult to access (Fig. 4C). This is consistent with the finding that treatment with 0.5 mM/2 min NPM had no effect on rP2X2 V252C (Fig. 1F), although the position corresponding to P2X3-G189 in rP2X2 is also glycine (G201, Fig. 4A, C).
We constructed a chimera homology model in which the corresponding regions of P2X2 that constitute the pocket, including the LF and LB domains, were replaced with identical sequences of P2X3 (Fig. 4D) and added a substitution of I67V to obtain a new chimera P2X2gain (Fig. 4E, F). Analysis of the pocket properties of this chimera by TRAPP web server (https://trapp.h-its.org/trapp) [56] revealed that the heterologous pocket became larger rather than smaller after MD simulations, a result of upward motion of LF domain (Fig. 4F-H) during simulations. These results suggested that sequence variants of the LF, LB and DF domains could influence the shape of this site.

In the simulation system, we further integrated AF-219 into the P2X2gain model (Fig. 5A), where the binding pattern of AF-219 remained consistent with the crystal structure of the hP2X3/AF-219 complex (Fig. 5B). On this basis, MD simulations of the AF-219/P2X2gain complex showed that the contact of AF-219 and P2X2gain did not change significantly before and after MD simulations (Fig. 5C), unlike its extrusion from the pocket in the P2X2 WT channels (Fig. 3D-E). hP2X3 (Fig. 5D) and rP2X2gain (Fig. 5E) interactions with the AF-219 were monitored throughout the MD simulations. These interactions were categorized by type and summarized into three types: hydrogen bonds (green), hydrophobic (light blue), and water bridges (blue). The stacked bar charts were normalized over the course of the trajectory (values over 1.0 are possible as some protein residue may make multiple contacts of the same subtype with the ligand). The timeline representation of the interactions and contacts between hP2X3 (F) and rP2X2gain (G) with AF-219 monitored throughout the MD simulations (some residues made more than one specific contact with the ligand were represented by a darker shade of orange). Only the binding site residues interacting with the ligand are marked with numbers. These analyses indicated that AF-219 had interactions with V250, L277, D278, G279, K188, N202 and L203 of P2X2gain (corresponding to V238, D266, S267, S275, G277, K176, N190 and L191 of P2X3), which is essentially comparable to interactions of AF-219 and hP2X3 that observed in the crystal structure (Fig. 5D, E).

To verify this point, the chimeras rP2X2LF, rP2X2LBD/DF, rP2X2LF/LBD/DF and rP2X2gain were obtained by stepwise substitution of the amino acids constituting the rP2X2 binding pocket (Fig. 6A). rP2X2LBD/DF substitution only mildly enhanced the antagonistic effect of AF-353 (IC50 > 100 nM), whereas in the case of both substitutions, i.e., rP2X2LF/LBD/DF and rP2X2gain were obtained by stepwise substitution of amino acids constituting the rP2X2 binding pocket (Fig. 6A), the antagonistic effect of AF-353 can be increased ~20-fold (IC50 = 0.33 ± 0.02 μM, Fig. 6B).
In addition, further mutations based on rP2X2\textsuperscript{gain}, rP2X2\textsuperscript{gain}-G201A (corresponding to G189 of rP2X3) or rP2X2\textsuperscript{gain}-L203A (a residue corresponding to L191 of rP2X3, whose backbone atom forms hydrogen bonding interaction with AF-219; rP2X3 L191A almost fully abolished the inhibition of AF-353 and AF-219[42]), greatly weakened the antagonistic effect of AF-353 in rP2X2\textsuperscript{gain} (Fig. 6C, D). These results again validate the important influence of G201 as a key residue at the entrance of the pocket and suggest that the protein–ligand interaction of rP2X2\textsuperscript{gain}/AF-353 is similar to that exhibited in the P2X3/AF-219 crystal structure.

3.5. In addition to the binding site amino acids directly contacting with AF-353/AF-219, other amino acids also have an impact on ligand recognition

Although we replaced almost all amino acids around the AF-219 binding site in rP2X2, rP2X2\textsuperscript{gain} and rP2X3\textsuperscript{WT} still differ ~20–50-fold in IC\textsubscript{50} values of AF-353 and AF-219, suggesting that structural elements outside the allosteric site also have an effect on the binding and action of these allosteric modulators. Sequence differences in the non-binding site may lead to slight differences in the properties of the allosteric site. To test this idea, we synthesized AF-219-1 and AF-219-2, two compounds that differ slightly from the AF-219 and AF-353 (Fig. 7A). If the pockets of rP2X2\textsuperscript{gain} and rP2X3\textsuperscript{WT} maintained exactly the same conformation, the different AF-219/AF-353 analogs would exhibit the same alteration in the concentration response curves of P2X2\textsuperscript{gain} versus P2X3\textsuperscript{WT}. Under the condition that the amino acids forming the allosteric pocket of P2X2\textsuperscript{gain} and P2X3\textsuperscript{WT} are nearly identical, these differences may be caused by the different amino acid residues outside the pocket.

4. Discussion

P2X receptors are currently gaining attention as an important new class of drug targets [60]. The crystal structures of several subtypes have been determined, and drug discovery of P2X receptors is no longer limited to the traditional high-throughput screening. New drug development and chemical structure optimization by means of computer-aided design or artificial intelligence approaches will be another important strategy [42,61]. The success of AF-219 in phase III clinical trials has prompted us to extensively investigate its mechanism of action [9,62,63]. Although we have identified the site of action of AF-219 previously [42], the development of new drugs at this site still requires our understanding of the mechanism by which AF-219 selectively acts at the P2X3 receptor.

In the crystal structure of P2X3 complexed with AF-219, the small molecule is bound in a pocket consisting of the LF and LB domains and forms hydrogen bonding interactions with main chain atoms of N190/L191 [42]. From the results of NPM modifications, this pocket is also present in P2X1, P2X2, and P2X4, and some amino acids interacting with AF-219, such as N190, V238 and...
D266, are highly conserved in different subtypes of P2X. Although some amino acids such as L191 have isoleucine replacement in other subtypes, AF-219 interacts only with the backbone atoms at that position. Thus, each P2X receptor subtype has its own specificity of allosteric sites [64], and the selective action of AF-219 on the P2X3 receptor is determined not only by differences in the amino acid sequences with which it interacts directly, but also by amino acids outside the pocket.

The accessibility of the binding pocket affects the action of AF-219 in two ways. First, the amino acid at the entrance of the pocket is glycine in rP2X3, ensuring that AF-219 enters this pocket smoothly. Any small change including G189A causes a dramatic effect on the ATP current of rP2X3WT (B) and rP2X2mut (C). The data of AF-353 are the same as shown in Figs. 3F and 6B and are shown here for comparison. The data are shown as mean ± SEM (n = 3–6).

5. Conclusion

Although we previously identified the site and mechanism of action of AF-219 on the P2X3 receptor, which occupies a pocket consisting of the left flipper and lower body (LB) domains, the mechanism by which Gefapixant/AF-219 selectively acts on the P2X3 receptor is unclear. We suggest here that the negative allosteric site of AF-219 at P2X3 is also present in other P2X subtypes and the selectivity of AF-219 or AF-353 for P2X3 over other P2X subtypes is determined by the accessibility of its binding site and the shape constraints of its pocket, a finding that will provide new perspectives for drug design against P2X3-mediated diseases such as RCC, idiopathic pulmonary fibrosis and overactive bladder disorder.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This study was supported with funds from the Natural Science Foundation of Jiangsu Province (BK20202002 to Y. Y.), National Natural Science Foundation of China with grant numbers 32000869 (J. W.), 31900808 (W. -H. W.), 31971146 (Y. Y.) and 32071234 (M.H.), Innovation and Entrepreneurship Talent Program of Jiangsu Province (Y. Y. and J. W.), State Key Laboratory of Utilization of Woody Oil Resource with grant number 2019XX2002 (C. -Z. L.), Hunan “Huxiang” High-level Talent Program (2021 to Y. Y) and “Xing Yao” Leading
Supporting Information

Supplementary data to this article can be found online at https://doi.org/10.1016/j.csbj.2022.03.030.

References

1. Breslow LA, Hoshino T, Grossman P, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
2. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
3. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
4. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
5. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
6. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
7. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
8. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
9. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
10. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
11. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
12. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
13. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
14. Huang L, Li Y, Zhang J, et al. Activation of the acid-sensing ion channel TRPV1 in the brainstem of rats with colitis. J Neuroinflammation 2012;9:126.
15. Hoshino T, Okumura T, Furutani T, et al. Characterization of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males. J Pharmacol Exp Ther 2014;350:25–32.
Coddou C, Yan Z, Obusi T, HuidoBro-Toro JP, Stojilkovic SS. Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev 2011;63:641–83.

Lewis CJ, Evans RJ. Lack of run-down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels. Br J Pharmacol 2000;131:1659–66.

Bitencourt-Ferreira G, de Azevedo WF, Jr. Homology Modeling of Protein Targets with MODELLER. Methods Mol Biol 2019;2053:231–49.

Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007;23:2947–8.

Laskowski RA, Macarthur MW, Moss DS, Thornton JM. Procheck - a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993;26:283–91.

Shaw DE. A fast, scalable method for the parallel evaluation of distance-limited pairwise particle interactions. J Comput Chem 2005;26:1318–28.

Lomize GA, Pogozheva ID, Joo H, Mosberg HJ, Lomize AL. OPM database and PPM web server: resources for positioning of proteins in membranes. Nucleic Acids Res 2012;40:D370–6.

Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2003;107:6474–87.

Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996;118:11225–36.

Le Guilloux V, Schmidtke P, Tuffery P. Ppocket: an open source platform for ligand pocket detection. BMC Bioinf 2009;10:168.

Yuan JH, Han SB, Richter S, Wade RC, Kokh DB. Druggability assessment in TRAPP using machine learning approaches. J Chem Inf Model 2020;60:1685–99.

Mansoor SE, Lu W, Oosterheert W, Shekhar M, Tajkhorshid E, Goaux E. X-ray structures define human P2X(3) receptor gating cycle and antagonist action. Nature 2016;538:66–71.